Medicare AdvantageCoverageMedium impact
MA08.070g, Golimumab (Simponi Aria®) Intravenous (IV) Injection
Independence Blue Cross·Rheumatology, Gastroenterology, Dermatology·Pharmacy
Effective date
Oct 1, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage updated their policy for Golimumab (Simponi Aria®) intravenous injection coverage, effective October 1, 2025. This affects billing and coverage requirements for this specialty infusion medication used primarily for autoimmune conditions.
Action Required
By October 1, 2025: Billing team must review updated Medicare Advantage coverage criteria for Golimumab (Simponi Aria®) IV injections. Update prior authorization workflows and verify current coverage requirements in billing system. Contact Medicare Advantage plans to confirm any new documentation or approval requirements for this medication.